Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent inhibitor of PARP-1 and PARP-2, with IC50 values of 5 nM and 1 nM, respectively, under standard enzymatic assay conditions (ApexBio datasheet). It induces synthetic lethality in tumor cells with homologous recombination deficiencies, especially those harboring BRCA1/2 or BAP1 mutations (Borchert et al., 2019). Olaparib increases apoptosis and senescence in BRCA-associated protein 1 (BAP1)-mutated mesothelioma models, and its efficacy is enhanced in combination with DNA-damaging agents such as cisplatin (Borchert et al., 2019). The compound's solubility profile is optimal in DMSO (≥21.72 mg/mL), and it is widely adopted in DNA damage response and tumor radiosensitization studies (ApexBio). Resistance mechanisms—such as intact ATM kinase activity—limit its activity to specific genetic backgrounds, emphasizing the need for biomarker-guided study design.

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are key enzymes involved in DNA single-strand break repair via base excision repair (BER). Tumor cells with defective homologous recombination repair (HRR), such as those with BRCA1, BRCA2, or BAP1 mutations, exhibit increased reliance on PARP-mediated DNA repair (Borchert et al., 2019). Inhibiting PARP activity in these backgrounds leads to the accumulation of DNA lesions and cell death—a concept known as synthetic lethality. This rationale underpins the application of Olaparib (AZD2281, Ku-0059436) in targeted therapy research for BRCA-associated and homologous recombination-deficient cancers.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

• Olaparib competitively inhibits the catalytic activity of PARP-1 and PARP-2, key mediators of BER (ApexBio).
• The compound binds to the NAD⁺ binding site, preventing PARylation of target proteins.
• In HR-deficient cells (e.g., with BRCA1/2 mutations), PARP inhibition leads to unrepaired single-strand breaks that collapse replication forks, resulting in double-strand breaks and apoptosis (Borchert et al., 2019).
• Olaparib also "traps" PARP enzymes on DNA, resulting in cytotoxic protein-DNA complexes.
• The cytotoxicity is selective for cells lacking effective HR pathways, sparing most normal cells.

Evidence & Benchmarks

• Olaparib exhibits IC50 values of 5 nM (PARP-1) and 1 nM (PARP-2) in in vitro enzymatic assays (ApexBio).
• BAP1-mutated and BRCA-deficient malignant pleural mesothelioma (MPM) cells display increased apoptosis and senescence upon olaparib treatment compared to wild-type controls (Borchert et al., 2019).
• Combination of olaparib with cisplatin yields synergistic cytotoxicity in HR-deficient tumor models (Borchert et al., 2019).
• Gene expression profiling identifies approximately 10% of MPM patient tumors as displaying BRCAness phenotypes, which correlate with olaparib sensitivity (Borchert et al., 2019).
• In murine xenograft models, olaparib (50 mg/kg/day, i.p., 14 days) enhances radiosensitivity and impairs tumor progression (ApexBio).
• ATM-deficient cell lines are more sensitive to olaparib, confirming the role of ATM in DNA repair redundancy (Borchert et al., 2019).

Applications, Limits & Misconceptions

Olaparib is widely used for:

• DNA damage response assays in BRCA1/2- and BAP1-mutated cancer models.
• Radiosensitization studies in non-small cell lung carcinoma (NSCLC) and mesothelioma xenograft models.
• Targeted therapy development for homologous recombination-deficient tumors.

This article extends prior overviews (see in-depth mechanistic analysis) by providing updated, peer-reviewed benchmarks and a focus on experimental limitations. For comparison, the previous guide details troubleshooting and experimental workflows, whereas this dossier emphasizes genetic and phenotypic determinants of response.

Common Pitfalls or Misconceptions

• Olaparib is not universally effective; tumors with intact homologous recombination repair (HRR) show resistance.
• BRCA1/2 mutations are not the sole predictors of sensitivity; “BRCAness” phenotype must be confirmed by gene expression profiling.
• Olaparib is not soluble in ethanol or water—use DMSO for all stock solutions.
• Long-term storage of olaparib solutions at ≥-20°C is not recommended; prepare fresh aliquots for each experiment.
• ATM-proficient cells or those with redundant repair pathways may not respond to PARP inhibition.

Workflow Integration & Parameters

• Solubility: ≥21.72 mg/mL in DMSO; insoluble in ethanol and water (ApexBio).
• Storage: Below -20°C as solid; avoid long-term storage in solution.
• In vitro dosing: 10 μM for 1 hour in cell culture assays is standard.
• In vivo dosing (mouse): 50 mg/kg/day intraperitoneally for 14 days (ApexBio).
• Assay selection: Use apoptosis, senescence, and DNA damage markers as readouts (e.g., caspase activation, γH2AX foci).
• Genetic profiling: Confirm HR deficiency or BRCAness via molecular assays before experimental treatment.

For advanced integration strategies, this article discusses the translational application of olaparib with competitive landscape analysis—complementing the present focus on genetic determinants and protocol parameters.

Conclusion & Outlook

Olaparib (AZD2281) remains an indispensable tool for dissecting PARP-mediated DNA repair and advancing targeted cancer therapy in HR-deficient contexts. Ongoing research emphasizes the importance of biomarker-driven experimental design to maximize translational impact. Future directions include expanded profiling of BRCAness, optimized radiosensitization protocols, and combination regimens tailored to molecular vulnerabilities. For detailed product specifications and ordering, refer to the A4154 kit page.